Nanovare SAS

Nanovare SAS operates as a fertility technology company that provides at-home sperm testing services, empowering individuals to gain insights into their reproductive health through convenient testing solutions. Founded in 2014 by Daniel Thomas and Mo Taha, Nanovare SAS is headquartered in Lyon, France. The company has completed a total of 4 deals, with its most recent financing event occurring on October 21, 2021. In this venture round, Nanovare raised EUR 1.

81 million, bringing the total amount raised to EUR 1. 81 million and achieving a company valuation of EUR 11. 40 million. Returning investor Inventure and new investor Crista Galli Ventures participated in this funding round.

Mojo specializes in at-home sperm testing services designed to provide individuals with insights into their reproductive health. The core offering is the Mojo sperm testing kit, which allows users to collect and send sperm samples for analysis, eliminating the need for clinic visits. The service includes comprehensive testing covering various biomarkers essential for assessing sperm health, with results delivered within 48 hours. Targeted primarily at men who are exploring fertility options or seeking to enhance their reproductive health, the customer base includes individuals trying to conceive as well as those proactively assessing their fertility.

The company operates primarily within the UK market, focusing on the growing demand for convenient and private health solutions. Mojo generates revenue through the direct sale of its sperm testing kits, which are offered at various pricing tiers depending on the complexity of the tests chosen. Customers place orders online, and upon receiving their kits, they perform home sample collection and send it back for analysis using included return labels. The company’s business model operates on a direct-to-consumer basis, allowing for streamlined transactions without intermediaries.

In addition to the testing service, Mojo may offer optional consultations with fertility specialists, further enhancing its service offering. This approach supports a consumer-friendly experience while addressing the specific needs of individuals inquiring about their fertility health. Following its EUR 1. 81 million funding round in October 2021, Nanovare SAS plans to utilize the capital to enhance product development, potentially launching new fertility-related products.

The company aims to expand its market presence beyond the UK in the near future. Specific markets targeted for expansion have not been disclosed, but the company's growth strategy indicates a focus on increasing accessibility to its services for a broader audience.